ESKAPE pathogens
Antimicrobial resistance is recog-
nized
as one of the
greatest threats
to human
health worldwide. The ESKAPE pathogens:
• Enterococcus faecium,
• Staphylococcus aureus,
• Klebsiella pneumoniae,
• Acinetobacter baumanii,
• Pseudomonas aeruginosa,
• Enterobacter species
cause the majority of hospital
infec-
tions.
Resistant
ESKAPE
bacteria
are not
killed by the antibiotics that
have
been so beneficial
to humanity.
Concerns about acquired bacterial
resistance
towards antibiotics are
high in the Nordic
countries,
the
Netherlands and Switzerland.
When other developed countries
want, or have
to,
acknowledge the
problems of resistance,
the market
for alternative wound treatment
therapies is
expected to grow
significantly.
|
|
MRSA - Methicillin Resistant Staphylococcus aureus
Staphylococcus aureus
colonizes skin in about
30%
of
healthy humans.
The bac-
terium is very
adaptive to changing
environments.
MRSA accelerated its
global
appearance with
an especial-
ly
invasive
form that spread
rapidly
from Australia around
1960.
Due to its resistance
towards
antibiotics,
MRSA
today cau-
ses
healthcare associated
infections
worldwide. |
 |
 |
MRSA (image: wikimedia) |
Risk groups
MRSA is normally
not harmful to healthy people. When bacteria are
introduced to blood stream,
or in
people with suppressed immune
system,
the infection may become life
threatening
Common environments for MRSA spreading are: close contact areas
like hospitals,
elderly
at
homes,
children at day care and athletes in
contact sports.
Also contacts with farmed pigs appear to involve
elevated risks.
Suffering and Costs
16% of all Hospital Acquired Infections in USA
were caused by
resistant bacteria (NHSN 2008). Resistant bacteria increase mortality by 50%, and the cost for each infected patient was 2008 $ 21 000 [Roberts et al., Clinical Infectious Diseases 49 (2009) 1175-1184].
The total annual extra costs for resistant infections in the US healthcare system during 2008 has been estimated to
$ 20 US billion (= $ 20 milliard) [IDSA], [CDC 2013]. |
|